• Colgate-Palmolive recently declared a quarterly cash dividend of US$0.53 per common share, payable on August 14, 2026, to shareholders of record on July 20, 2026, while reporting broad-based first-quarter 2026 growth in net sales, organic sales, profitability, and free cash flow.
• These results, alongside uninterrupted dividends since 1895 and 36 consecutive annual increases, underscore Colgate-Palmolive’s emphasis on consistent cash returns and operational improvement across its oral care, home care, personal care, and pet nutrition businesses.
• Against this backdrop of stronger margins and organic sales growth, we’ll explore how the latest quarter reshapes Colgate-Palmolive’s existing investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Colgate-Palmolive Investment Narrative Recap

To own Colgate-Palmolive, you need to believe in its ability to steadily grow its global oral, home, personal care and pet nutrition franchises while converting that into reliable cash returns. The latest dividend affirmation and solid first quarter do not materially change the near term focus on organic sales growth as the key catalyst, or the main risk that cautious consumers and category softness in markets like North America, Brazil and India could still hold back volumes.

Among the recent updates, the stronger first quarter 2026 results stand out as most relevant, with broad-based net and organic sales growth and higher margins supporting the company’s investment in marketing and innovation. This progress feeds directly into the thesis that productivity efforts and higher brand spending can help offset cost pressures and private label competition, especially as Colgate-Palmolive leans on its core oral care and growing pet nutrition businesses.

Yet against this reassuring backdrop, investors should still be aware of how persistent input cost inflation could...

Colgate-Palmolive's narrative projects $22.8 billion revenue and $3.5 billion earnings by 2029. This requires 3.8% yearly revenue growth and a $1.4 billion earnings increase from $2.1 billion today.

Uncover how Colgate-Palmolive's forecasts yield a $96.68 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Four Simply Wall St Community valuations for Colgate-Palmolive range from US$87 to about US$120 per share, highlighting very different expectations. Set this against the current focus on organic sales growth as the key catalyst and consider how varying growth assumptions can shape your own view of the company’s prospects.

Explore 4 other fair value estimates on Colgate-Palmolive - why the stock might be worth as much as 34% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Colgate-Palmolive research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.